Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization Against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza Type B in Infants

NCT02257645 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT02257645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization Against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza Type B in Infants
Lead sponsor
LG Life Sciences
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2015
Completion date
September 30, 2016
Enrollment
3,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenza type b, hepatitis b, pertussis, tetanus